Anti Cancer

European Medical Agency to Review Biocon’s Anti Cancer Biosimilar Trastuzumab

European Medicines Agency (EMA) has accepted for review Mylan‘s application to market biosimilar Trastuzumab, co-developed with Biocon, that is used to…

Read More »